跳至主要内容
临床试验/EUCTR2004-002641-12-IT
EUCTR2004-002641-12-IT进行中(未招募)不适用

A multicenter, multinational, phase 3B, open-label extension trial to assess the safety and tolerability of long-term treatment of rotigotine patch in subjects with idiopathic Parkinson s disease

SCHWARZ PHARMA0 个研究点目标入组 220 人开始时间: 2007年2月2日最近更新:

试验速览

阶段
不适用
状态
进行中(未招募)
入组人数
220

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range

排除标准

  • 未提供

研究者

相似试验

进行中(未招募)
1 期
A multicenter, multinational, phase 3b, open-label extension trial to assess the safety and tolerability of long-term treatment of rotigotine patch in subjects with idiopathic Parkinson's diseaseParkinson's disease
EUCTR2004-002641-12-GBSchwarz Biosciences GmbH220
进行中(未招募)
不适用
A multicenter, multinational, phase 3b, open-label extension trial to assess the safety and tolerability of long-term treatment of rotigotine patch in subjects with idiopathic Parkinson's diseaseParkinson's disease
EUCTR2004-002641-12-ATSchwarz Biosciences GmbH220
进行中(未招募)
1 期
A multicenter, multinational, phase 3b, open-label extension trial to assess the safety and tolerability of long-term treatment of rotigotine patch in subjects with idiopathic Parkinson's diseaseParkinson's disease
EUCTR2004-002641-12-ESSchwarz Biosciences GmbH220
进行中(未招募)
不适用
A multicenter, multinational, phase 3b, open label extension trial, to evaluate the long term effect of the 24 hour transdermal delivery of rotigotine on motor function, sleep quality, and nocturnal and non motor symptoms in subjects with idiopathic Parkinson disease. - SP915, Long term extension of RECOVERPatient with Idiopathic Parkinson DieseaseMedDRA version: 9.1Level: LLTClassification code 10061536Term: Parkinson's disease
EUCTR2006-006907-35-ITSCHWARZ PHARMA270
进行中(未招募)
不适用
A phase 3b, open-label, multicenter, multinational trial to evaluate the effects of rotigotine transdermal patch on early morning motor impairment and sleep disorders in patients with idiopathic Parkinson's diseaseParkinson's Disease
EUCTR2004-002598-21-ATSchwarz Biosciences GmbH50